This article has been updated from an earlier version to include stock price.

NEW YORK, Oct. 27 (GenomeWeb News) - Shares in Orchid Cellmark were down 27.48 percent, or $2.30, at $6.07, in mid-afternoon trading after the company reported flat third-quarter revenues amid declining R&D spending and surging net losses.

 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.